Phaseline

Targets › NS5A

NS5A: drug programs, companies and trials

8 programs from 8 companies in 9 trials: 5 Phase 4, 2 Phase 2, 2 Phase 3; Infectious disease, Cardiovascular, Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on NS5A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Oswaldo Cruz FoundationEpclusa 400Mg-100Mg Tablet
HCV NS5A inhibitor and nucleotide NS5B polymerase inhibitor combination
NS5A, NS5BPhase 4Hepatitis CDec 2026
LifespanSofosbuvir
RNA-directed RNA polymerase inhibitor
NS5B, NS5APhase 4HEPATITIS C (HCV)Jan 2027
Catherine Anne ChappellSofosbuvir
RNA-directed RNA polymerase inhibitor
NS5B, NS5APhase 4Hepatitis C, ChronicAug 2027
Kirby InstitutePibrentasvir
Nonstructural protein 5A inhibitor
NS3, NS5APhase 4Hepatitis CJul 2029
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sofosbuvir
RNA-directed RNA polymerase inhibitor
NS5B, NS5APhase 4Diabetes MellitusDec 2032
Atea PharmaceuticalsBemnifosbuvir-Ruzasvir (BEM/RZR)
HCV NS5B polymerase inhibitor and NS5A inhibitor combination
NS5B, NS5APhase 3HEPATITIS C VIRUS CHRONIC INFECTIONDec 2026
Baylor Research InstituteSofosbuvir
RNA-directed RNA polymerase inhibitor
NS5B, NS5APhase 2Heart FailureDec 2026
Amit D Tevar, MDSofosbuvir
RNA-directed RNA polymerase inhibitor
NS5B, NS5APhase 2Kidney Transplantation–

Conditions

Hepatitis C (2) HEPATITIS C VIRUS CHRONIC INFECTION (2) HEPATITIS C (HCV) (1) Hepatitis C, Chronic (1) Heart Failure (1) Diabetes Mellitus (1) Kidney Transplantation (1)

Modalities

small molecule (8)

Companies

Lifespan (1) Catherine Anne Chappell (1) Oswaldo Cruz Foundation (1) Kirby Institute (1) Baylor Research Institute (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Atea Pharmaceuticals (1) Amit D Tevar, MD (1)

Related targets

NS5B (7) NS3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.